CA2336904A1 - Novel fluorescent lanthanide chelates - Google Patents
Novel fluorescent lanthanide chelates Download PDFInfo
- Publication number
- CA2336904A1 CA2336904A1 CA002336904A CA2336904A CA2336904A1 CA 2336904 A1 CA2336904 A1 CA 2336904A1 CA 002336904 A CA002336904 A CA 002336904A CA 2336904 A CA2336904 A CA 2336904A CA 2336904 A1 CA2336904 A1 CA 2336904A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- dtpa
- iii
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052747 lanthanoid Inorganic materials 0.000 title claims description 23
- 150000002602 lanthanoids Chemical class 0.000 title claims description 21
- 238000003556 assay Methods 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims description 32
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 238000004166 bioassay Methods 0.000 claims description 15
- 108010004469 allophycocyanin Proteins 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 8
- 238000001917 fluorescence detection Methods 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 6
- 102000053602 DNA Human genes 0.000 claims description 5
- 229940058934 aminoquinoline antimalarials Drugs 0.000 claims description 5
- 150000003248 quinolines Chemical class 0.000 claims description 5
- 150000005010 aminoquinolines Chemical class 0.000 claims description 4
- 238000002372 labelling Methods 0.000 claims description 4
- 229920005646 polycarboxylate Polymers 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical class NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical class NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 claims description 2
- WBMPYOXBHLVYMK-UHFFFAOYSA-N 1-amino-10h-acridin-9-one Chemical class N1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N WBMPYOXBHLVYMK-UHFFFAOYSA-N 0.000 claims description 2
- KHUFHLFHOQVFGB-UHFFFAOYSA-N 1-aminoanthracene-9,10-dione Chemical class O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N KHUFHLFHOQVFGB-UHFFFAOYSA-N 0.000 claims description 2
- IEUANVROPGDRIN-UHFFFAOYSA-N 2-aminochromeno[3,2-b]pyridin-10-one Chemical class C1=CC=C2C(=O)C3=NC(N)=CC=C3OC2=C1 IEUANVROPGDRIN-UHFFFAOYSA-N 0.000 claims description 2
- BELZLSZHWJZDNM-UHFFFAOYSA-N 2-aminofluoren-1-one Chemical class C1=CC=C2C3=CC=C(N)C(=O)C3=CC2=C1 BELZLSZHWJZDNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 10
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 claims 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 abstract description 7
- 239000003504 photosensitizing agent Substances 0.000 abstract description 5
- 239000008139 complexing agent Substances 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229960003330 pentetic acid Drugs 0.000 description 13
- -1 lanthanide cations Chemical class 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000975 dye Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 150000005016 6-aminoquinolines Chemical class 0.000 description 4
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- LNPMZQXEPNWCMG-UHFFFAOYSA-N 4-(2-aminoethyl)aniline Chemical compound NCCC1=CC=C(N)C=C1 LNPMZQXEPNWCMG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001952 enzyme assay Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RBKHNGHPZZZJCI-UHFFFAOYSA-N (4-aminophenyl)-phenylmethanone Chemical compound C1=CC(N)=CC=C1C(=O)C1=CC=CC=C1 RBKHNGHPZZZJCI-UHFFFAOYSA-N 0.000 description 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 1
- RVGFNHMYNPTXRT-UHFFFAOYSA-N 2-(4-isothiocyanatophenyl)ethanamine Chemical compound NCCC1=CC=C(N=C=S)C=C1 RVGFNHMYNPTXRT-UHFFFAOYSA-N 0.000 description 1
- BHUDMBBYUOGKQI-UHFFFAOYSA-N 2-amino-8-bromo-10-oxochromeno[3,2-b]pyridine-3-carbonitrile;2-amino-8-ethyl-10-oxochromeno[3,2-b]pyridine-3-carbonitrile Chemical compound O1C2=CC=C(Br)C=C2C(=O)C2=C1C=C(C#N)C(N)=N2.N#CC1=C(N)N=C2C(=O)C3=CC(CC)=CC=C3OC2=C1 BHUDMBBYUOGKQI-UHFFFAOYSA-N 0.000 description 1
- JIDPRRVEJMGZKE-UHFFFAOYSA-N 2-aminoxanthen-9-one Chemical compound C1=CC=C2C(=O)C3=CC(N)=CC=C3OC2=C1 JIDPRRVEJMGZKE-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- 150000005014 3-aminoquinolines Chemical class 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 150000000918 Europium Chemical class 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- FBJXAUCDHRYFHZ-UHFFFAOYSA-N NC1=NC=2C(C3=CC=CC=C3OC2C=C1C#N)=O.NC=1C=CC=2C(C3=CC=CC=C3NC2C1)=O Chemical compound NC1=NC=2C(C3=CC=CC=C3OC2C=C1C#N)=O.NC=1C=CC=2C(C3=CC=CC=C3NC2C1)=O FBJXAUCDHRYFHZ-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001443 photoexcitation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- RJSRSRITMWVIQT-UHFFFAOYSA-N quinolin-6-amine Chemical compound N1=CC=CC2=CC(N)=CC=C21 RJSRSRITMWVIQT-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0026—Acridine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
Abstract
The present invention provides complexing agents of Formula (I) which contain novel photosensitizers and produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
Description
NOVEL FLUORESCENT LANTHANIDE CHELATES
FIELD OF INVENTION
The present invention relates to the identification and preparation of organic agents that can complex lanthanide cations. In particular, this invention relates to complexing agents which contain novel photosensitizers and can produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
BACKGROUND OF THE INVENTION
A wide variety of bioassays are used in the pharmaceutical industry to identify drug development candidate compounds. Recent advances in the identification of pharmaceutical targets, together with the vastly increased output of new compounds using techniques such as combinatorial chemistry have created a need to increase bioassay throughput (number of samples measured per unit time) drastically to meet discovery objectives. Robotics, miniaturization and homogeneous assay formats have all been incorporated into high throughput screening (HTS) assays to increase throughput. Ideally, an analytical technique suitable for both miniaturization and homogeneous assay formats must provide maximal detection sensitivity and interaction in situ, while requiring only minimal assay time and liquid handling (e.g., separation and filtration).
Present analytical techniques, such as those which use radiolabels, are unsatisfactory for HTS
use because they lack sensitivity, require large sample size and manual liquid handling.
Compared to traditional radiolabels, fluorescent labels have more desirable lifetime, solubility and sensitivity properties for use in HTS assays. The unique lifetime properties of fluorescent labels also meet the needs of fluorescence polarization (FP) and fluorescence correlation spectroscopy (FCS) in the investigation of slow rotational and translational changes in macromolecules.
Traditional fluorescent labels such as organic dyes, e.g., fluoresceins and rhodamines, have long been employed as bioanalytical tools in immunoassays.
More recently; lanthanide chelates have been developed as fluorescence agents for use in the bioassay field. These lanthanide chelates _have been reviewed. See Dickson, J.
Photochemistrv and Photobiolo~v, 27 (1995) 3-19; and Mathis, J. Clinical Lig~d Assav 20 (I997)141-145.
The lanthanide chelates are capable of producing long-lived and long wavelength fluorescent emissions upon excitation. In time-delay measurements, they have demonstrated clear advantages over conventional fluorescent labels, in particular less quenching and background interference, while exhibiting increased detection sensitivity. In addition to these advantages, many lanthanide chelates have demonstrated superior solubility properties and are able to efficiently transfer energy from their excited states to neighboring acceptor molecules. These advantages render lanthanide chelates ideal agents for HTRF use, especially for developing high-throughput automated and miniaturized binding assays, inncluding immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays.
A number of lanthanide (e.g. terbium, europium) complexes are known, but only three classes of lanthanide chelates, exemplified by the compounds shown in Table I below, are considered to be useful in HTRF:
Table I
Cryptates (Packard) bipyridine type; i.e.
DTPA Chelates (Berkeley) ""e diethylenetriamine-pentaacetic 0 N N NH(CH2~OH
-~ ~ ~ ~ ~---.
acid type; i.e. " H
O HOOC COON COON O
Eu+3.
PMDA Chelates (Wallac) "~" N °°°F' pyridylmethylamine-diacetic ~ ~ / ~N ~°°eH Eu+3 HzN -acid type; i.e. /~°°°"
N
---COON
FIELD OF INVENTION
The present invention relates to the identification and preparation of organic agents that can complex lanthanide cations. In particular, this invention relates to complexing agents which contain novel photosensitizers and can produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
BACKGROUND OF THE INVENTION
A wide variety of bioassays are used in the pharmaceutical industry to identify drug development candidate compounds. Recent advances in the identification of pharmaceutical targets, together with the vastly increased output of new compounds using techniques such as combinatorial chemistry have created a need to increase bioassay throughput (number of samples measured per unit time) drastically to meet discovery objectives. Robotics, miniaturization and homogeneous assay formats have all been incorporated into high throughput screening (HTS) assays to increase throughput. Ideally, an analytical technique suitable for both miniaturization and homogeneous assay formats must provide maximal detection sensitivity and interaction in situ, while requiring only minimal assay time and liquid handling (e.g., separation and filtration).
Present analytical techniques, such as those which use radiolabels, are unsatisfactory for HTS
use because they lack sensitivity, require large sample size and manual liquid handling.
Compared to traditional radiolabels, fluorescent labels have more desirable lifetime, solubility and sensitivity properties for use in HTS assays. The unique lifetime properties of fluorescent labels also meet the needs of fluorescence polarization (FP) and fluorescence correlation spectroscopy (FCS) in the investigation of slow rotational and translational changes in macromolecules.
Traditional fluorescent labels such as organic dyes, e.g., fluoresceins and rhodamines, have long been employed as bioanalytical tools in immunoassays.
More recently; lanthanide chelates have been developed as fluorescence agents for use in the bioassay field. These lanthanide chelates _have been reviewed. See Dickson, J.
Photochemistrv and Photobiolo~v, 27 (1995) 3-19; and Mathis, J. Clinical Lig~d Assav 20 (I997)141-145.
The lanthanide chelates are capable of producing long-lived and long wavelength fluorescent emissions upon excitation. In time-delay measurements, they have demonstrated clear advantages over conventional fluorescent labels, in particular less quenching and background interference, while exhibiting increased detection sensitivity. In addition to these advantages, many lanthanide chelates have demonstrated superior solubility properties and are able to efficiently transfer energy from their excited states to neighboring acceptor molecules. These advantages render lanthanide chelates ideal agents for HTRF use, especially for developing high-throughput automated and miniaturized binding assays, inncluding immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays.
A number of lanthanide (e.g. terbium, europium) complexes are known, but only three classes of lanthanide chelates, exemplified by the compounds shown in Table I below, are considered to be useful in HTRF:
Table I
Cryptates (Packard) bipyridine type; i.e.
DTPA Chelates (Berkeley) ""e diethylenetriamine-pentaacetic 0 N N NH(CH2~OH
-~ ~ ~ ~ ~---.
acid type; i.e. " H
O HOOC COON COON O
Eu+3.
PMDA Chelates (Wallac) "~" N °°°F' pyridylmethylamine-diacetic ~ ~ / ~N ~°°eH Eu+3 HzN -acid type; i.e. /~°°°"
N
---COON
3 PC'T/US99/15366 These chelates have been described as having chemical stability, long-lived fluorescence (greater than 0.1 ms lifetime) after bioconjugation and significant energy-transfer in specific bioaffinity assays. US5162508, issued to Lehn, et al. on November 10, 1992 discloses bipyridine cryptates. Polycarboxylate chelators with TEKES type photosensitizers (EP 0203047 AI) and terpyridine type photosensitizers (EP
0649020 A1) are known. International Publication No. WO 96/00901 of Selvin et al., having an International Publication Date of January 11, 1996, discloses diethylenetriaminepentaacetic acid (DTPA) chelates which used carbostyril as sensitizes. Bailey, et al., Analyst, 109, (1984) 1449; Ando, et al. Biochim. Bioph~s. Acta, 1102, (1992) 186; and Heyduk et al., Anal. Biochemistry, 248, (1997) 216 also describe DTPA lanthanide chelates which contain different sensitizers. Additional DTPA chelates with other sensitizers and other tracer metals are known for diagnostic or imaging use (e.g., EP 0450742 A1).
The lanthanide chelates provided by the present invention include novel sensitizers which differ from carbostyril and other known chelates. More specifically, these novel sensitizers impart onto the present chelates advantageous physicochemical properties pertaining to excitation wavelength, lifetime, quantum yield, quenching effect, complex stability, photostability, solubility, charge, nonspecific protein interaction, biocoupling efficiency and ease of preparation. Such advantages are desirable to provide a diversity of novel fluorescent probes for use in, and development of, HTRF assays.
SUMMARY OF THE INVENTION
An object of the present invention is to provide novel lanthanide chelate compounds, and a method for using such compounds in fluorescence detection-based techniques or bioassays.
Accordingly, in the first aspect, this invention provides a compound according to Formula I.
In still another aspect, this invention provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays.
In yet another aspect, this invention provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement.
DETAILED DESCRIPTION OF THE INVENTION
Each compound of the present invention comprises four functional parts: a lanthanide metal cation (e.g. Tb III, Eu III, Sm III, Dy III), a chelator for the lanthanide metal, a photosensitizer for photoexcitation and energy transfer, and a linker for bioconjugation to the target biomolecule, that is, the biomolecule being measured using a fluorescence detection -based spectroscopic technique or bioassay.
The present invention provides compounds of Formula I:
O O
R2 ~ ~R1 N~N~N
n O
O OH O OH
OH
wherein:
[~N/~]n is a chelator selected from the group consisting of:
diethylenetriaminepentaacetic acid (DTPA) (n = I) or triethylenetetraaminehexaacetic acid (TTHA) (n =2) or a polyaminocarboxylate derivative of DTPA or TTHA, preferably DTPA, which chelates a lanthanide metal cation, preferably selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
The sensitizer R1 is usually related to an aromatic or heteroaromatic amine whose chromophore plays a vital role in excitation and energy transfer. Superior sensitizers usually have highly conjugated systems and an added capacity for lanthanide complexation.
We have found several sensitizers, belonging to two structural classes-phenones and quinolines - that provide highly fluorescent compounds of Formula I. R1 is more preferably selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino-azaxanthones (AAX), aminoanthraquinones (AAQ), and aminoacridones (AAC):
0649020 A1) are known. International Publication No. WO 96/00901 of Selvin et al., having an International Publication Date of January 11, 1996, discloses diethylenetriaminepentaacetic acid (DTPA) chelates which used carbostyril as sensitizes. Bailey, et al., Analyst, 109, (1984) 1449; Ando, et al. Biochim. Bioph~s. Acta, 1102, (1992) 186; and Heyduk et al., Anal. Biochemistry, 248, (1997) 216 also describe DTPA lanthanide chelates which contain different sensitizers. Additional DTPA chelates with other sensitizers and other tracer metals are known for diagnostic or imaging use (e.g., EP 0450742 A1).
The lanthanide chelates provided by the present invention include novel sensitizers which differ from carbostyril and other known chelates. More specifically, these novel sensitizers impart onto the present chelates advantageous physicochemical properties pertaining to excitation wavelength, lifetime, quantum yield, quenching effect, complex stability, photostability, solubility, charge, nonspecific protein interaction, biocoupling efficiency and ease of preparation. Such advantages are desirable to provide a diversity of novel fluorescent probes for use in, and development of, HTRF assays.
SUMMARY OF THE INVENTION
An object of the present invention is to provide novel lanthanide chelate compounds, and a method for using such compounds in fluorescence detection-based techniques or bioassays.
Accordingly, in the first aspect, this invention provides a compound according to Formula I.
In still another aspect, this invention provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays.
In yet another aspect, this invention provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement.
DETAILED DESCRIPTION OF THE INVENTION
Each compound of the present invention comprises four functional parts: a lanthanide metal cation (e.g. Tb III, Eu III, Sm III, Dy III), a chelator for the lanthanide metal, a photosensitizer for photoexcitation and energy transfer, and a linker for bioconjugation to the target biomolecule, that is, the biomolecule being measured using a fluorescence detection -based spectroscopic technique or bioassay.
The present invention provides compounds of Formula I:
O O
R2 ~ ~R1 N~N~N
n O
O OH O OH
OH
wherein:
[~N/~]n is a chelator selected from the group consisting of:
diethylenetriaminepentaacetic acid (DTPA) (n = I) or triethylenetetraaminehexaacetic acid (TTHA) (n =2) or a polyaminocarboxylate derivative of DTPA or TTHA, preferably DTPA, which chelates a lanthanide metal cation, preferably selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
The sensitizer R1 is usually related to an aromatic or heteroaromatic amine whose chromophore plays a vital role in excitation and energy transfer. Superior sensitizers usually have highly conjugated systems and an added capacity for lanthanide complexation.
We have found several sensitizers, belonging to two structural classes-phenones and quinolines - that provide highly fluorescent compounds of Formula I. R1 is more preferably selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino-azaxanthones (AAX), aminoanthraquinones (AAQ), and aminoacridones (AAC):
WO 00/01663 PC'T/US99/15366 NHz / \ I / NHz i O AAP O
ABP
NH2 _ , , NHz \ / \ /
O AX
NHz NHz \ /
O AAX AAQ
NHz O AAC
wherein for each nucleus, the amino group NH2 may be attached at one of any possible positions on the phenyl ring. The point of amide attachment to the chelator [~Nn]n in Formula I may similarly be attached at one of any possible positions on the phenyl ring. R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, N02, C02H, C02CH3, I; Br and Cl.
Sensitizers of the present invention belonging to the quinoline class can be further categorized into 3- aminoquinolines (3AQ), and 6-aminoquinolines (6AQ).
Preferably in the quinoline compounds of the present invention, Rl is selected from the group consisting IO of:
\ \ NH2 H2N \ \
wherein R3 and R4 are as defined herein above.
The linker R2 is an amine or other moiety having a functional group that can bioconjugate or can be derivatized to couple with biomolecules. In a preferred embodiment of the present invention, R2 is selected from the group consisting of: OH, NH(CH2)nOH, NH(CH2)nNH2, NH(CH2)nPhNH2, NH(CH2)nPhOH, NHCH(C02H)CH2PhNH2,, NH(CH2)nPhNCS; wherein n is 1-12. The present invention also contemplates the use of other linkers known in the art for coupling.
Particularly preferred compounds of the present invention include the DTPA
chelates listed in Table II below:
Table II
Formula R1 R2 Lifetime msec Lanthanide Eu Tb I 3AAP - 0.59 1.73 I 3AQ - 0.59 I 6AQ - 0.60 I 4ABP - 0.60 1.03 I 3AAP 4APEA 0.50 1.62 I 3AAP 4APEA-ITC 0.62 1.65 I 3AAP 4APA 0.60 1.70 I 6AQ CAD 0.58 I 4ABP 4APEA 0.43 0.73 I 4ABP CAD 0.59 0.82 Abbreviations:
3AAP: 4-aminoacetophenone 3AQ: 3-aminoquinoline 6AQ: 6-aminoquinoline 4ABP: 4-aminobenzophenone 4APEA: 4-aminophenethylamine 4APEA-ITC: 4-isothiocyanatophenethylamine 4APA: 4-aminophenylalanine DTPA: Diethylene-triamine-pentaacetic acid TTHA: Triethylene-tetramine-hexaacetic acid CAD: Cadaverine or 1,5-diaminopentane More particularly preferred compounds of the present invention include the DTPA
chelates below:
% O / / O /
\ \ \ \
NH ~ v ~NH
O O
7-amino-1-azaxanth-5-one 2-amino-xanthone (7AAX) (2AX) N / NH / O j NH
\ ) \
v O O N
3-amino-acridone 2-amino-3-cyano-azaxanthone (3AAC) (2ACAX) / O j NH / O N NH
\I \
Br N \N
O O
2-amino-3-cyano-7-bromo-azaxanthone 2-amino-3-cyano-7-ethyl-azaxanthone (2ACBAX) {2ACEAX) Dei'initions Sensitizes and chelator moiety abbreviations are as defined in Table II above.
The terms "bioconjugate" and "bioconjugatable" mean the ability of a functional group or groups on a chemical moiety to form covalent linkage to biomolecules.
The term "polycarboxylate derivative of DTPA or TTHA" means a compound which differs from DTPA and TTHA by changing the length of N-acetic acid units, or by rearranging the units from a linear to a cyclic form.
The term "bioassay" means immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like.
Method of Preparation The sensitizers and space linkers with structures described herein above are employed in a manner shown in Scheme I and in the Examples. The first step in the synthetic route involves reacting the sensitizes amine, hereby exemplified by aminoacetophenone, with equal or higher molar ratio of DTPAA (diethylene-triamine-pentaacetic anhydride) in the presence of triethylamine. The product formed is not isolated but allowed to react with an equal or a slight molar excess of the linker amine, hereby exemplified by 4-aminophenethylamine. The disubstituted derivative is then isolated and purified by HPLC before convening the linker amino group into a bioconjugatable function. The final step is to react the product (Compound 5} with thiophosgene in a slightly acidic condition to form the isothiocyanate (Compound 6).
Alternatively, a chlorotirazine derivative instead of an isothiocyanate can also be prepared from Compound 5 for facile labelling of target molecules with a reactive amino function.
WO 00/O1b63 PCT/US99/15366 \ a HsC \ ~ b ~ H ~ O --HC
s ~ NHZ O N~\ /~N~
N O
O ~O
O OH
OH
NHZ
O O
HaC \ \ C
H~ ~H
O N~ ~N ~'"
N O
O OH ~ O OH
off s O O / ~ Ni H3C \ H~ ~H \
O N~ SIN
N O
O OH ~ O OH
OH
a) DTPAA, DMSO, Et3N; b) 4APEA, DMSO, Et3N; c) CSC12, MeCl2-H2O
Utility of the Invention The compounds of this invention can be used for labelling donor peptides, proteins, DNAs, enzyme substrates, ligand molecules in immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like. These bioassays can be also formated for ultrasensitive high-throughput screening assays. In the bioassay, the lanthanide chelate is excited in a fluorescence instrument and provide energy transfer to an acceptor molecule such as an organic dye (e.g. allophycocyanin (APC), or indodicarbocyanin or CY-5) capable of providing the desired long-lived fluorescense emission for quantitation.
The present invention also provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays. The present method comprises the steps of:
labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I
by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
2. adding a suitable amount of a suitable organic dye, preferably selected from the group consisting of: allophycocyanin (APC) and indodicarbocyanin (CY-5), to the labelled biomolecule assay sample;
3. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
Fluorescence instruments suitable for use in the inventive method include the Photon Technology International, Model LS-100, Luminescence System.
The present invention further provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement, such kit comprising:
1. a suitable amount of a compound of Formula I; and 2. a suitable amount of organic dye, preferably selected from the group consisting of: allophycocyanin (APC), indodicarbocyanin (CY-5) and rhodamine.
Such a kit provides instructions for proper use thereof, including the appropriate amounts of the compound of Formula I and the organic dye to use for a particular bioassay sample molecular type and size.
General Proton NMR spectra were recorded at 400 MHz using a Bruker AMX 400 spectrometer. CDC13 is deuteriochloroform, DMSO-d6 is hexadeuteriodimethylsulfoxide, and) CD30D is tetradeuteriomethanol. Chemical shifts are reported in parts per million (d) downfield from the internal standard tetramethylsilane. Abbreviations for NMR
data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm'1). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF
instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques.
Examples In the following synthetic examples, temperature is in degrees Centigrade (°C).
Unless otherwise indicated, all of the starting materials were obtained from commercial sources. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
These Examples are given to illustrate the invention, not to limit its scope. Reference is made to the claims for what is reserved to the inventors hereunder.
Referring to Table II and the Method of Preparation section:
Example 1 Preparation of 3AAP-DTPA (1) and 3AAP-DTPA-4APEA (5) To a solution of DTPAA ( 143 mg, 0.4 mmol) in 10 mL dry DMSO and 2 mL dry triethylamine was added a solution of 3-arninoacetophenone (3AAP, 54 mg, 0.4 mmol) in 5 mL DMSO. The mixture was stirred at room temperature for 0.5 h and then treated with a solution of 4-aminophenethylamine (4APEA, 53 mg, 0.4 mmol) in 5 mL DMSO. The mixture was allowed to stir at room temperature for an additional 3 h and then evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hpic (using a step gradient of 0 to 60% acetonitrile in 0.1 % TFA buffer) to give, after Iyophilization, 1 as a cream colored solid and 5 as a pale yellow solid. Compound 1 was obtained in 59 mg yield. 1H-NMR (CD30D) : d 2.60 (3H, s), 3.1-3.5 (IOH, m), 3.6 (2H, s), 3.65 (2H, s), 3.71 (2H, s), 4.42 (2H, s), 7.42 ( 1 H, dd), 7.75 ( 1 H, dd), 7.83 ( 1 H, dd), 8.31 ( 1 H, d); MS: m/z 511 (M-H), Compound 5 was obtained in 16 mg yield. 1 H-NMR (CD30D): d 2.62 (3H, s), 2.73 (2H, t), 3.21 (2H, t), 3.3-3.55 ( 12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.35 (2H, s), 7.13 (4H, s), 7.41 ( 1 H, dd), 7.75 ( 1 H, dd), 7.83 ( 1 H, dd), 8.32 ( 1 H,d); MS
: m/z 682 (M+ 3NH4), 683 (MH+ 3NH4).
Example 2 Preparation of 4AAP-DTPA-APEA-ITC (6).
To a solution of 4AAP-DTPA-APEA (3, 12 mg, 0.019 mmol) in 10 mL of 0.5 N
HCl was added 4mL of thiophosgene (85% in CC14). The two phase reaction was allowed to stirred vigorously for I h . The mixture was worked up by separating the layers in a separatory funnel and the aqueos solution was washed by additional methylene chloride and then chromatographed on a small reversed-phase C18 column to give the thioisocyanate WO 00/OI663 PCT/US99/t5366 product (6), an off white solid in 10 mg yield after lyophilization. 1H-NMR
(CD30D):
2.60 (3H, s), 2.72 (2H, t), 3.20 {2H, t), 3.3-3.5 ( 12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.34 (2H, s), 7.12 (4H, s), 7.41 ( 1 H, ss), 7.74 ( I H, dd), 7.84 ( 1 H, dd), 8.20 ( I H,d); MS: m/z 724 (M+3NH4), 725 (MH+ 3NH4); IR: 2108 cm-1 (S=C=N stretch).
Example 3 Preparation of 4ABP-DTPA (4) and 4ABP-DTPA-4APEA (12) To a solution of DTPAA (179 mg, 0.5 mmol) in 5 mL of dry DMSO and 3 mL of dry triethylamine was added a solution of 4-aminobenzophenone (4ABP, 99 mg, 0.5 mmol) in 5 mL DMSO. The mixture was stirred for 0.5 h and treated with a solution of aminophenethylamine (4APEA, 68 mg, 0.05 mmol) in 5 mL DMSO. After an additional 3 h stirnng at room temperature, the mixture was evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hplc (using a step gradietn of 0-60%
acetonitrile in 0.1 % TFA buffer) to give 4 as a cream colored solid and 12 as a pale yellow solid. Compound 4 was obtained in 57 mg yield. 1H-NMR {CD30D): d 3.2-3.5 (IOH, m), 3.60 (2H, s), 3.63 (2H, s), 3.74 (2H, s), 4.43 (2H, s), 7.53 (2H, m), 7.62 ( 1 H, dd), 7.76 (2H, m), 7.8 (4H, s); MS: mlz 573 (M+H). Compound 12 was obtained in 47 mg yield.
IH-NMR (CD30D): d 2.73 (2H, t), 3.25 (2H, t), 3.3-3.5 (12H, m), 3.67 (2H, s), 3.73 (2H, s), 4.3 (2H, s), 7.23 (4H, s), 7.55 (2H, m), 7.64 (1H, dd), 7.8 (2H, m), 7.83 (4H, m); MS:
mlz 691 (M+H).
The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.
ABP
NH2 _ , , NHz \ / \ /
O AX
NHz NHz \ /
O AAX AAQ
NHz O AAC
wherein for each nucleus, the amino group NH2 may be attached at one of any possible positions on the phenyl ring. The point of amide attachment to the chelator [~Nn]n in Formula I may similarly be attached at one of any possible positions on the phenyl ring. R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, N02, C02H, C02CH3, I; Br and Cl.
Sensitizers of the present invention belonging to the quinoline class can be further categorized into 3- aminoquinolines (3AQ), and 6-aminoquinolines (6AQ).
Preferably in the quinoline compounds of the present invention, Rl is selected from the group consisting IO of:
\ \ NH2 H2N \ \
wherein R3 and R4 are as defined herein above.
The linker R2 is an amine or other moiety having a functional group that can bioconjugate or can be derivatized to couple with biomolecules. In a preferred embodiment of the present invention, R2 is selected from the group consisting of: OH, NH(CH2)nOH, NH(CH2)nNH2, NH(CH2)nPhNH2, NH(CH2)nPhOH, NHCH(C02H)CH2PhNH2,, NH(CH2)nPhNCS; wherein n is 1-12. The present invention also contemplates the use of other linkers known in the art for coupling.
Particularly preferred compounds of the present invention include the DTPA
chelates listed in Table II below:
Table II
Formula R1 R2 Lifetime msec Lanthanide Eu Tb I 3AAP - 0.59 1.73 I 3AQ - 0.59 I 6AQ - 0.60 I 4ABP - 0.60 1.03 I 3AAP 4APEA 0.50 1.62 I 3AAP 4APEA-ITC 0.62 1.65 I 3AAP 4APA 0.60 1.70 I 6AQ CAD 0.58 I 4ABP 4APEA 0.43 0.73 I 4ABP CAD 0.59 0.82 Abbreviations:
3AAP: 4-aminoacetophenone 3AQ: 3-aminoquinoline 6AQ: 6-aminoquinoline 4ABP: 4-aminobenzophenone 4APEA: 4-aminophenethylamine 4APEA-ITC: 4-isothiocyanatophenethylamine 4APA: 4-aminophenylalanine DTPA: Diethylene-triamine-pentaacetic acid TTHA: Triethylene-tetramine-hexaacetic acid CAD: Cadaverine or 1,5-diaminopentane More particularly preferred compounds of the present invention include the DTPA
chelates below:
% O / / O /
\ \ \ \
NH ~ v ~NH
O O
7-amino-1-azaxanth-5-one 2-amino-xanthone (7AAX) (2AX) N / NH / O j NH
\ ) \
v O O N
3-amino-acridone 2-amino-3-cyano-azaxanthone (3AAC) (2ACAX) / O j NH / O N NH
\I \
Br N \N
O O
2-amino-3-cyano-7-bromo-azaxanthone 2-amino-3-cyano-7-ethyl-azaxanthone (2ACBAX) {2ACEAX) Dei'initions Sensitizes and chelator moiety abbreviations are as defined in Table II above.
The terms "bioconjugate" and "bioconjugatable" mean the ability of a functional group or groups on a chemical moiety to form covalent linkage to biomolecules.
The term "polycarboxylate derivative of DTPA or TTHA" means a compound which differs from DTPA and TTHA by changing the length of N-acetic acid units, or by rearranging the units from a linear to a cyclic form.
The term "bioassay" means immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like.
Method of Preparation The sensitizers and space linkers with structures described herein above are employed in a manner shown in Scheme I and in the Examples. The first step in the synthetic route involves reacting the sensitizes amine, hereby exemplified by aminoacetophenone, with equal or higher molar ratio of DTPAA (diethylene-triamine-pentaacetic anhydride) in the presence of triethylamine. The product formed is not isolated but allowed to react with an equal or a slight molar excess of the linker amine, hereby exemplified by 4-aminophenethylamine. The disubstituted derivative is then isolated and purified by HPLC before convening the linker amino group into a bioconjugatable function. The final step is to react the product (Compound 5} with thiophosgene in a slightly acidic condition to form the isothiocyanate (Compound 6).
Alternatively, a chlorotirazine derivative instead of an isothiocyanate can also be prepared from Compound 5 for facile labelling of target molecules with a reactive amino function.
WO 00/O1b63 PCT/US99/15366 \ a HsC \ ~ b ~ H ~ O --HC
s ~ NHZ O N~\ /~N~
N O
O ~O
O OH
OH
NHZ
O O
HaC \ \ C
H~ ~H
O N~ ~N ~'"
N O
O OH ~ O OH
off s O O / ~ Ni H3C \ H~ ~H \
O N~ SIN
N O
O OH ~ O OH
OH
a) DTPAA, DMSO, Et3N; b) 4APEA, DMSO, Et3N; c) CSC12, MeCl2-H2O
Utility of the Invention The compounds of this invention can be used for labelling donor peptides, proteins, DNAs, enzyme substrates, ligand molecules in immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like. These bioassays can be also formated for ultrasensitive high-throughput screening assays. In the bioassay, the lanthanide chelate is excited in a fluorescence instrument and provide energy transfer to an acceptor molecule such as an organic dye (e.g. allophycocyanin (APC), or indodicarbocyanin or CY-5) capable of providing the desired long-lived fluorescense emission for quantitation.
The present invention also provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays. The present method comprises the steps of:
labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I
by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
2. adding a suitable amount of a suitable organic dye, preferably selected from the group consisting of: allophycocyanin (APC) and indodicarbocyanin (CY-5), to the labelled biomolecule assay sample;
3. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
Fluorescence instruments suitable for use in the inventive method include the Photon Technology International, Model LS-100, Luminescence System.
The present invention further provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement, such kit comprising:
1. a suitable amount of a compound of Formula I; and 2. a suitable amount of organic dye, preferably selected from the group consisting of: allophycocyanin (APC), indodicarbocyanin (CY-5) and rhodamine.
Such a kit provides instructions for proper use thereof, including the appropriate amounts of the compound of Formula I and the organic dye to use for a particular bioassay sample molecular type and size.
General Proton NMR spectra were recorded at 400 MHz using a Bruker AMX 400 spectrometer. CDC13 is deuteriochloroform, DMSO-d6 is hexadeuteriodimethylsulfoxide, and) CD30D is tetradeuteriomethanol. Chemical shifts are reported in parts per million (d) downfield from the internal standard tetramethylsilane. Abbreviations for NMR
data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm'1). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF
instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques.
Examples In the following synthetic examples, temperature is in degrees Centigrade (°C).
Unless otherwise indicated, all of the starting materials were obtained from commercial sources. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
These Examples are given to illustrate the invention, not to limit its scope. Reference is made to the claims for what is reserved to the inventors hereunder.
Referring to Table II and the Method of Preparation section:
Example 1 Preparation of 3AAP-DTPA (1) and 3AAP-DTPA-4APEA (5) To a solution of DTPAA ( 143 mg, 0.4 mmol) in 10 mL dry DMSO and 2 mL dry triethylamine was added a solution of 3-arninoacetophenone (3AAP, 54 mg, 0.4 mmol) in 5 mL DMSO. The mixture was stirred at room temperature for 0.5 h and then treated with a solution of 4-aminophenethylamine (4APEA, 53 mg, 0.4 mmol) in 5 mL DMSO. The mixture was allowed to stir at room temperature for an additional 3 h and then evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hpic (using a step gradient of 0 to 60% acetonitrile in 0.1 % TFA buffer) to give, after Iyophilization, 1 as a cream colored solid and 5 as a pale yellow solid. Compound 1 was obtained in 59 mg yield. 1H-NMR (CD30D) : d 2.60 (3H, s), 3.1-3.5 (IOH, m), 3.6 (2H, s), 3.65 (2H, s), 3.71 (2H, s), 4.42 (2H, s), 7.42 ( 1 H, dd), 7.75 ( 1 H, dd), 7.83 ( 1 H, dd), 8.31 ( 1 H, d); MS: m/z 511 (M-H), Compound 5 was obtained in 16 mg yield. 1 H-NMR (CD30D): d 2.62 (3H, s), 2.73 (2H, t), 3.21 (2H, t), 3.3-3.55 ( 12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.35 (2H, s), 7.13 (4H, s), 7.41 ( 1 H, dd), 7.75 ( 1 H, dd), 7.83 ( 1 H, dd), 8.32 ( 1 H,d); MS
: m/z 682 (M+ 3NH4), 683 (MH+ 3NH4).
Example 2 Preparation of 4AAP-DTPA-APEA-ITC (6).
To a solution of 4AAP-DTPA-APEA (3, 12 mg, 0.019 mmol) in 10 mL of 0.5 N
HCl was added 4mL of thiophosgene (85% in CC14). The two phase reaction was allowed to stirred vigorously for I h . The mixture was worked up by separating the layers in a separatory funnel and the aqueos solution was washed by additional methylene chloride and then chromatographed on a small reversed-phase C18 column to give the thioisocyanate WO 00/OI663 PCT/US99/t5366 product (6), an off white solid in 10 mg yield after lyophilization. 1H-NMR
(CD30D):
2.60 (3H, s), 2.72 (2H, t), 3.20 {2H, t), 3.3-3.5 ( 12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.34 (2H, s), 7.12 (4H, s), 7.41 ( 1 H, ss), 7.74 ( I H, dd), 7.84 ( 1 H, dd), 8.20 ( I H,d); MS: m/z 724 (M+3NH4), 725 (MH+ 3NH4); IR: 2108 cm-1 (S=C=N stretch).
Example 3 Preparation of 4ABP-DTPA (4) and 4ABP-DTPA-4APEA (12) To a solution of DTPAA (179 mg, 0.5 mmol) in 5 mL of dry DMSO and 3 mL of dry triethylamine was added a solution of 4-aminobenzophenone (4ABP, 99 mg, 0.5 mmol) in 5 mL DMSO. The mixture was stirred for 0.5 h and treated with a solution of aminophenethylamine (4APEA, 68 mg, 0.05 mmol) in 5 mL DMSO. After an additional 3 h stirnng at room temperature, the mixture was evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hplc (using a step gradietn of 0-60%
acetonitrile in 0.1 % TFA buffer) to give 4 as a cream colored solid and 12 as a pale yellow solid. Compound 4 was obtained in 57 mg yield. 1H-NMR {CD30D): d 3.2-3.5 (IOH, m), 3.60 (2H, s), 3.63 (2H, s), 3.74 (2H, s), 4.43 (2H, s), 7.53 (2H, m), 7.62 ( 1 H, dd), 7.76 (2H, m), 7.8 (4H, s); MS: mlz 573 (M+H). Compound 12 was obtained in 47 mg yield.
IH-NMR (CD30D): d 2.73 (2H, t), 3.25 (2H, t), 3.3-3.5 (12H, m), 3.67 (2H, s), 3.73 (2H, s), 4.3 (2H, s), 7.23 (4H, s), 7.55 (2H, m), 7.64 (1H, dd), 7.8 (2H, m), 7.83 (4H, m); MS:
mlz 691 (M+H).
The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.
Claims (10)
1. A compound of Formula I:
[\N~]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA) (n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
R1 is selected from the group consisting of: phenones and quinolines; and R2 is selected from the group consisting of: OH, NH(CH2)n OH, NH(CH2)n NH2, NH(CH2)n PhNH2, NH(CH2)n PhOH, NHCH(CO2H)CH2PhNH2, NH(CH2)n PhNCS;
wherein n is 1-6.
[\N~]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA) (n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
R1 is selected from the group consisting of: phenones and quinolines; and R2 is selected from the group consisting of: OH, NH(CH2)n OH, NH(CH2)n NH2, NH(CH2)n PhNH2, NH(CH2)n PhOH, NHCH(CO2H)CH2PhNH2, NH(CH2)n PhNCS;
wherein n is 1-6.
2. A compound according to Claim 1 wherein R1 is selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino-azaxanthones (AAX), aminoanthraquinones (AAQ), aminoacridones (AAC), and aminoquinolines (AQ):
wherein R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, NO2, CO2H, and CO2CH3.
wherein R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, NO2, CO2H, and CO2CH3.
3. A compound according to Claim 1 wherein R1 is selected from the following group:
4. A compound according to Claim 1 wherein [~N~]n is DTPA (n= 1).
5. A compound according to Claim 1 wherein the lanthanide metal cation is selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
6. A compound according to Claim 5 wherein the lanthanide metal cation is selected from the group consisting of: Eu III or Tb III.
7. A method for using a compound of Formula I:
wherein:
[~N~]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA) (n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
R1 is selected from the group consisting of: phenones and quinolines; and R2 is selected from the group consisting of: OH, NH(CH2)n OH, NH(CH2)n NH2, NH(CH2)n PhNH2, NH(CH2)n PhOH, NHCH(CO2H)CH2PhNH2, NH(CH2)n PhNCS;
wherein n is 1-6;
in fluorescence detection-based techniques or bioassays comprising the steps of:
a. labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I
by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
b. adding a suitable amount of a suitable organic dye to the labelled biomolecule assay sample;
c. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
wherein:
[~N~]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA) (n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
R1 is selected from the group consisting of: phenones and quinolines; and R2 is selected from the group consisting of: OH, NH(CH2)n OH, NH(CH2)n NH2, NH(CH2)n PhNH2, NH(CH2)n PhOH, NHCH(CO2H)CH2PhNH2, NH(CH2)n PhNCS;
wherein n is 1-6;
in fluorescence detection-based techniques or bioassays comprising the steps of:
a. labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I
by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
b. adding a suitable amount of a suitable organic dye to the labelled biomolecule assay sample;
c. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
8. A method according to Claim 7 wherein said organic dye is selected from the group consisting of but not limited to: rhodamine, allophycocyanin (APC) and indodicarbocyanin (CY-5),
9. A kit for fluorescence detection-based techniques or bioassays comprising:
a. a suitable amount of a compound of Formula I; and b. a suitable amount of organic dye.
a. a suitable amount of a compound of Formula I; and b. a suitable amount of organic dye.
10. A kit according to Claim 9 wherein said organic dye is selected from the group consisting of but not limited to: rhodamine, allophycocyanin (APC) and indodicarbocyanin (CY-5).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9194498P | 1998-07-07 | 1998-07-07 | |
US60/091,944 | 1998-07-07 | ||
PCT/US1999/015366 WO2000001663A1 (en) | 1998-07-07 | 1999-07-07 | Novel fluorescent lanthanide chelates |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2336904A1 true CA2336904A1 (en) | 2000-01-13 |
Family
ID=22230424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002336904A Abandoned CA2336904A1 (en) | 1998-07-07 | 1999-07-07 | Novel fluorescent lanthanide chelates |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1095011A4 (en) |
JP (1) | JP2002519404A (en) |
CA (1) | CA2336904A1 (en) |
WO (1) | WO2000001663A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440389B1 (en) * | 2000-07-19 | 2002-08-27 | The General Hospital Corporation | Fluorescent agents for real-time measurement of organ function |
CA2424370A1 (en) | 2000-10-19 | 2002-04-25 | Exxonmobil Chemical Patents Inc. | Cationic group-3 catalyst system |
DE10163295B4 (en) | 2001-12-21 | 2004-03-25 | Honeywell Specialty Chemicals Seelze Gmbh | Rare earth metal compounds and mixtures thereof, processes for their preparation and their use |
DE102004022628A1 (en) * | 2004-05-07 | 2005-12-15 | Sensient Imaging Technologies Gmbh | FRET bioassay |
DE102004024011A1 (en) * | 2004-05-14 | 2005-12-01 | Bayer Chemicals Ag | Difluoro-1,3-dioxole |
WO2006014645A1 (en) * | 2004-07-23 | 2006-02-09 | Amgen Inc. | Generic probes for the detection of phosphorylated sequences |
CN101010107A (en) * | 2004-08-26 | 2007-08-01 | 马林克罗特公司 | Luminescent metal complexes for monitoring renal function |
EP1885817B1 (en) * | 2005-05-11 | 2016-05-11 | University Of Durham | Responsive luminescent lanthanide complexes |
DK1885817T3 (en) | 2005-05-11 | 2016-08-22 | Univ Durham | Luminescent lanthanide OF RESPONSE |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
GB2451106A (en) * | 2007-07-18 | 2009-01-21 | Cis Bio Int | Lanthanide (III) ion complexing pyrazoyl-aza(thio)xanthone comprising compounds, their complexes and their use as fluorescent labels |
EP2480891B1 (en) | 2009-09-24 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction |
HUE045270T2 (en) | 2010-01-05 | 2019-12-30 | Inst Nat Sante Rech Med | Flt3 receptor antagonists for the treatment or the prevention of pain disorders |
DE102011001368B4 (en) | 2011-03-17 | 2013-01-31 | Bundesanstalt für Materialforschung und -Prüfung (BAM) | Lanthanoid chelates containing particles, their preparation and their use in bioanalysis |
DE102011101207B3 (en) | 2011-05-11 | 2012-05-10 | Sartorius Stedim Biotech Gmbh | Fluorescent dye for pH sensor |
EP2710381A2 (en) | 2011-05-16 | 2014-03-26 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for screening substances capable of modulating the replication of an influenza virus |
US20150276760A1 (en) | 2012-10-04 | 2015-10-01 | INSERM (Institut National de la Sante Et de la Recherche Medicate) | Method for Screening a Compound Capable of Inhibiting the Notch1 Transcriptional Activity |
DK3108255T3 (en) | 2014-02-18 | 2020-11-09 | Inst Nat Sante Rech Med | PROCEDURES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY NRP-1 / OBR COMPLEX SIGNAL ROUTE |
EP3131922B1 (en) | 2014-04-17 | 2020-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides and uses thereof for reducing cd95-mediated cell motility |
WO2020144324A1 (en) | 2019-01-11 | 2020-07-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for screening inhibitors against chikungunya virus and for determining whether subjects are predisposed to infection by said virus |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162508A (en) * | 1987-12-18 | 1992-11-10 | Compagnie Oris Industrie | Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers |
US5622821A (en) * | 1994-06-29 | 1997-04-22 | The Regents Of The University Of California | Luminescent lanthanide chelates and methods of use |
DE19505960A1 (en) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Conjugate for the individual dosage of drugs |
GB9813776D0 (en) * | 1998-06-25 | 1998-08-26 | Smithkline Beecham Plc | Novel compounds |
-
1999
- 1999-07-07 CA CA002336904A patent/CA2336904A1/en not_active Abandoned
- 1999-07-07 WO PCT/US1999/015366 patent/WO2000001663A1/en not_active Application Discontinuation
- 1999-07-07 JP JP2000558068A patent/JP2002519404A/en active Pending
- 1999-07-07 EP EP99932334A patent/EP1095011A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1095011A1 (en) | 2001-05-02 |
JP2002519404A (en) | 2002-07-02 |
WO2000001663A1 (en) | 2000-01-13 |
EP1095011A4 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2336904A1 (en) | Novel fluorescent lanthanide chelates | |
JP5335236B2 (en) | Lanthanide chelates and their use in bioassays | |
US5132432A (en) | Chemically reactive pyrenyloxy sulfonic acid dyes | |
JP5548363B2 (en) | Novel fluorescent dyes and their use | |
US8541555B2 (en) | Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | |
CN106232771B (en) | The new chromophore architectures of lanthanide chelate | |
US6277984B1 (en) | Monomethine cyanines rigidized by a two-carbon chain | |
US6740756B1 (en) | Fluorescent lanthanide chelates | |
US20210395606A1 (en) | Chromophoric structures for macrocyclic lanthanide chelates | |
US6552199B1 (en) | Fluorescence dyes and their use as fluorescence markers | |
US7297690B2 (en) | Fluorescent lanthadine complex | |
US5958673A (en) | Fluorescent dye | |
DE60214709T2 (en) | Method for increasing the hydrophilicity of fluorescent marker compounds | |
US6441167B1 (en) | Cinoxacin lanthanide chelates and their use as biomolecular probes | |
WO2008140452A1 (en) | Novel hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers | |
JP2006234772A (en) | Method of detecting protein and fluorescent dye used for same | |
EP4103652A1 (en) | Fluorescent rhodamine dyes with enhanced cell permeability | |
US20040029290A1 (en) | Fluorescent dye complexes | |
US5151517A (en) | Derivatives of tetrahydro-2,3,6,7,1h,5h,11h-(1)benzopyrano(6,7,8,i,j)quinolizinone-11 usable as markers for organic compounds, particularly biological compounds with a view to their detection by chemiluminescence or fluorescence | |
CN115703771A (en) | Fluorescent dye and preparation method and application thereof | |
Mihaela et al. | Synthesis and biological application of a new 1, 2, 5-oxadiazolo [3, 4-c] pyridine moiety fluorescent marker |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |